Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) is expected to release its earnings data before the market opens on Tuesday, March 4th. Analysts expect Aptevo Therapeutics to post earnings of ($7.75) per share for the quarter.
Aptevo Therapeutics Stock Down 7.5 %
NASDAQ:APVO opened at $3.21 on Tuesday. Aptevo Therapeutics has a 52 week low of $3.01 and a 52 week high of $399.60. The firm’s fifty day moving average is $4.33 and its 200-day moving average is $222.04.
Wall Street Analysts Forecast Growth
Separately, StockNews.com initiated coverage on Aptevo Therapeutics in a report on Monday, December 9th. They set a “sell” rating for the company.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Featured Articles
- Five stocks we like better than Aptevo Therapeutics
- Breakout Stocks: What They Are and How to Identify Them
- Finding Hidden Gems: Unconventional Penny Stock Investing
- Quiet Period Expirations Explained
- Price Targets on NVIDIA Rise in Front of Earnings
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Archer Aviation Stock Skids: Mistaking Progress for Bad News?
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
